Mani Foroohar
Stock Analyst at Leerink Partners
(0.22)
# 4,545
Out of 4,707 analysts
945
Total ratings
43.8%
Success rate
-4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Therapeutics | Reiterated: Hold | $2 | $1.92 | +4.17% | 14 | Sep 9, 2026 | |
| ABSI Absci | Initiated Coverage: Buy | $12 | $8.91 | +34.68% | 1 | Jun 4, 2026 | |
| RGNX REGENXBIO | Maintained: Buy | $17 | $8.76 | +94.06% | 64 | May 15, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $100 → $154 | $99.53 | +54.73% | 54 | May 15, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $27 → $35 | $12.74 | +174.73% | 52 | Apr 27, 2026 | |
| CAMP Camp4 Therapeutics | Maintained: Buy | $8 → $9 | $4.40 | +104.55% | 7 | Apr 2, 2026 | |
| RCKT Rocket Pharmaceuticals | Rated: Hold | $7 → $11 | $3.71 | +196.50% | 55 | Mar 27, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintained: Hold | n/a | $85.11 | - | 56 | Mar 26, 2026 | |
| MRNA Moderna | Maintained: Sell | $12 | $140.33 | -91.45% | 89 | Feb 11, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Hold | $370 → $351 | $260.10 | +34.95% | 67 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $68 → $100 | $56.71 | +76.34% | 67 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $370 → $86 | $74.76 | +15.03% | 76 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 → $2 | $0.6634 | +201.48% | 16 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $18 | $4.76 | +278.15% | 16 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $74 | $54.78 | +35.09% | 27 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $14.63 | - | 41 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.44 | - | 34 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $51 → $48 | $57.42 | -16.41% | 2 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $12.73 | +57.17% | 9 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $26.83 | n/a | 20 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $27 | $20.03 | n/a | 12 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $1.54 | n/a | 32 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $38.13 | n/a | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $3.03 | n/a | 20 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $3.63 | n/a | 31 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.2535 | n/a | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $21 | $5.33 | n/a | 15 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $11.30 | n/a | 1 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $5 | $4.91 | n/a | 24 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $6 | $5.85 | n/a | 17 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $30.40 | n/a | 7 | Oct 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $216 → $197 | $20.94 | n/a | 3 | Nov 6, 2020 |
enGene Therapeutics
Sep 9, 2026
Reiterated: Hold
Price Target: $2
Current: $1.92
Upside: +4.17%
Absci
Jun 4, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $8.91
Upside: +34.68%
REGENXBIO
May 15, 2026
Maintained: Buy
Price Target: $17
Current: $8.76
Upside: +94.06%
Mirum Pharmaceuticals
May 15, 2026
Maintained: Buy
Price Target: $100 → $154
Current: $99.53
Upside: +54.73%
Intellia Therapeutics
Apr 27, 2026
Reiterated: Buy
Price Target: $27 → $35
Current: $12.74
Upside: +174.73%
Camp4 Therapeutics
Apr 2, 2026
Maintained: Buy
Price Target: $8 → $9
Current: $4.40
Upside: +104.55%
Rocket Pharmaceuticals
Mar 27, 2026
Rated: Hold
Price Target: $7 → $11
Current: $3.71
Upside: +196.50%
Arrowhead Pharmaceuticals
Mar 26, 2026
Maintained: Hold
Price Target: n/a
Current: $85.11
Upside: -
Moderna
Feb 11, 2026
Maintained: Sell
Price Target: $12
Current: $140.33
Upside: -91.45%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintained: Hold
Price Target: $370 → $351
Current: $260.10
Upside: +34.95%
Dec 15, 2025
Maintained: Buy
Price Target: $68 → $100
Current: $56.71
Upside: +76.34%
Dec 15, 2025
Maintained: Buy
Price Target: $370 → $86
Current: $74.76
Upside: +15.03%
Dec 15, 2025
Maintained: Buy
Price Target: $3 → $2
Current: $0.6634
Upside: +201.48%
Oct 21, 2025
Maintained: Buy
Price Target: $20 → $18
Current: $4.76
Upside: +278.15%
Oct 15, 2025
Maintained: Buy
Price Target: $56 → $74
Current: $54.78
Upside: +35.09%
Oct 15, 2025
Maintained: Buy
Price Target: n/a
Current: $14.63
Upside: -
Oct 15, 2025
Maintained: Hold
Price Target: n/a
Current: $3.44
Upside: -
Sep 25, 2025
Maintained: Buy
Price Target: $51 → $48
Current: $57.42
Upside: -16.41%
Sep 23, 2025
Reiterated: Buy
Price Target: $20
Current: $12.73
Upside: +57.17%
Sep 3, 2025
Maintained: Buy
Price Target: n/a
Current: $26.83
Upside: n/a
Aug 18, 2025
Maintained: Buy
Price Target: $32 → $27
Current: $20.03
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $3
Current: $1.54
Upside: n/a
Aug 12, 2025
Reiterated: Buy
Price Target: $70
Current: $38.13
Upside: n/a
Mar 6, 2025
Maintained: Hold
Price Target: $1
Current: $3.03
Upside: n/a
Aug 9, 2024
Maintained: Hold
Price Target: $1
Current: $3.63
Upside: n/a
Jul 15, 2024
Maintained: Buy
Price Target: n/a
Current: $0.2535
Upside: n/a
Nov 13, 2023
Maintained: Hold
Price Target: $21
Current: $5.33
Upside: n/a
Jun 8, 2023
Maintained: Sell
Price Target: n/a
Current: $11.30
Upside: n/a
May 23, 2023
Reiterated: Hold
Price Target: $6 → $5
Current: $4.91
Upside: n/a
Nov 14, 2022
Reiterated: Hold
Price Target: $5 → $6
Current: $5.85
Upside: n/a
Oct 19, 2021
Maintained: Hold
Price Target: n/a
Current: $30.40
Upside: n/a
Nov 6, 2020
Maintained: Buy
Price Target: $216 → $197
Current: $20.94
Upside: n/a